Columbus Clinical Services, LLC.

Miami, Florida 33215

5 studies enrolling now · 34 studies all time

What they study most

Asthma Acute, Atherosclerotic Cardiovascular Disease, Attention Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Depression, Bipolar Disorder, COPD Acute Exacerbation, COPD Exacerbation Acute, Cardiovascular Disease, Chronic Idiopathic Constipation, Chronic Pain, Colitis, Ulcerative

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder — Recruiting now
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Recruiting now
• Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients — Recruiting now
• Pelacarsen Roll-over Extension Program — Recruiting now
• Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Rademikibart IV for Acute Asthma and COPD Exacerbation — Starting soon
• Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — Running, not enrolling
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza — Running, not enrolling
• Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD — Completed
• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. — Completed
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies — Completed
• BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs) — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) — Completed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis — Completed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection — Completed
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder — Completed
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain — Completed
• Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee — Completed
• The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) — Completed
• The Plecanatide Chronic Idiopathic Constipation (CIC) Study — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza — Completed
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed
• Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects — Completed